Details

Autor(en) / Beteiligte

• Gudiol, C
• Albasanz-Puig, A
• Laporte-Amargós, J
• Pallarès, N
• Mussetti, A
• Ruiz-Camps, I
• Puerta-Alcalde, P
• Abdala, E
• Oltolini, C
• Akova, M
• Montejo, M
• Mikulska, M
• Martín-Dávila, P
• Herrera, F
• Gasch, O
• Drgona, L
• Paz Morales, H
• Brunel, A-S
• García, E
• Isler, B
• Kern, W V
• Morales, I
• Maestro-de la Calle, G
• Montero, M
• Kanj, S S
• Sipahi, O R
• Calik, S
• Márquez-Gómez, I
• Marin, J I
• Gomes, M Z R
• Hemmatti, P
• Araos, R
• Peghin, M
• Del Pozo, J L
• Yáñez, L
• Tilley, R
• Manzur, A
• Novo, A
• Carratalà, J

Titel

Clinical Predictive Model of Multidrug Resistance in Neutropenic Cancer Patients with Bloodstream Infection Due to Pseudomonas aeruginosa

Ist Teil von

• Antimicrobial agents and chemotherapy, 2020-03, Vol.64 (4)

Ort / Verlag

United States: American Society for Microbiology

Erscheinungsjahr

2020

Quelle

Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals

Beschreibungen/Notizen

• We aimed to assess the rate and predictive factors of bloodstream infection (BSI) due to multidrug-resistant (MDR) in neutropenic cancer patients. We performed a multicenter, retrospective cohort study including oncohematological neutropenic patients with BSI due to conducted across 34 centers in 12 countries from January 2006 to May 2018. A mixed logistic regression model was used to estimate a model to predict the multidrug resistance of the causative pathogens. Of a total of 1,217 episodes of BSI due to , 309 episodes (25.4%) were caused by MDR strains. The rate of multidrug resistance increased significantly over the study period (  = 0.033). Predictors of MDR BSI were prior therapy with piperacillin-tazobactam (odds ratio [OR], 3.48; 95% confidence interval [CI], 2.29 to 5.30), prior antipseudomonal carbapenem use (OR, 2.53; 95% CI, 1.65 to 3.87), fluoroquinolone prophylaxis (OR, 2.99; 95% CI, 1.92 to 4.64), underlying hematological disease (OR, 2.09; 95% CI, 1.26 to 3.44), and the presence of a urinary catheter (OR, 2.54; 95% CI, 1.65 to 3.91), whereas older age (OR, 0.98; 95% CI, 0.97 to 0.99) was found to be protective. Our prediction model achieves good discrimination and calibration, thereby identifying neutropenic patients at higher risk of BSI due to MDR The application of this model using a web-based calculator may be a simple strategy to identify high-risk patients who may benefit from the early administration of broad-spectrum antibiotic coverage against MDR strains according to the local susceptibility patterns, thus avoiding the use of broad-spectrum antibiotics in patients at a low risk of resistance development.